Fintel reports that on June 7, 2024, Jefferies upgraded their outlook for Collegium Pharmaceutical (NasdaqGS:COLL) from Hold to Buy.
Analyst Price Forecast Suggests 30.10% Upside
As of June 2, 2024, the average one-year price target for Collegium Pharmaceutical is 40.80. The forecasts range from a low of 39.39 to a high of $43.05. The average price target represents an increase of 30.10% from its latest reported closing price of 31.36.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Collegium Pharmaceutical is 598MM, an increase of 5.46%. The projected annual non-GAAP EPS is 3.10.
What is the Fund Sentiment?
There are 509 funds or institutions reporting positions in Collegium Pharmaceutical. This is an increase of 43 owner(s) or 9.23% in the last quarter. Average portfolio weight of all funds dedicated to COLL is 0.17%, an increase of 26.92%. Total shares owned by institutions increased in the last three months by 5.65% to 51,725K shares. 
The put/call ratio of COLL is 0.23, indicating a bullish outlook.
What are Other Shareholders Doing?
Eventide Asset Management holds 2,634K shares representing 8.05% ownership of the company. In its prior filing, the firm reported owning 2,630K shares , representing an increase of 0.14%. The firm increased its portfolio allocation in COLL by 21.33% over the last quarter.
Pacer Advisors holds 2,587K shares representing 7.91% ownership of the company. In its prior filing, the firm reported owning 2,175K shares , representing an increase of 15.93%. The firm increased its portfolio allocation in COLL by 21.86% over the last quarter.
CALF - Pacer US Small Cap Cash Cows 100 ETF holds 2,544K shares representing 7.78% ownership of the company. In its prior filing, the firm reported owning 1,502K shares , representing an increase of 40.97%. The firm increased its portfolio allocation in COLL by 31.07% over the last quarter.
IJR - iShares Core S&P Small-Cap ETF holds 2,211K shares representing 6.76% ownership of the company. In its prior filing, the firm reported owning 2,162K shares , representing an increase of 2.22%. The firm increased its portfolio allocation in COLL by 23.54% over the last quarter.
Rubric Capital Management holds 1,834K shares representing 5.61% ownership of the company. In its prior filing, the firm reported owning 2,758K shares , representing a decrease of 50.39%. The firm increased its portfolio allocation in COLL by 19.45% over the last quarter.
Collegium Pharmaceutical Background Information
(This description is provided by the company.)
Collegium Pharmaceutical Inc. is a specialty pharmaceutical company committed to being the leader in responsible pain management. Collegium's headquarters are located in Stoughton, Massachusetts.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
